Generic Name:
Omalizumab
Project Status:
Cancelled
Therapeutic Area:
Asthma, severe persistent
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
SR0035-000
Details
Submission Type:
Initial
Indications:
Asthma, severe persistent
Recommendation:
Request for reconsideration received on October 13, 2005 was deemed to include New Information (October 20, 2005). The drug will undergo review as a resubmission. A final Recommendation will not be issued at this time.